Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03753204 · ClinicalTrials.gov registry record · Phase 1
Salt-Sensitivity and Immunity Cell Activation
A Phase 1 study of Inflammation and High Blood Pressure, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03753204: Active Phase 1 study of Inflammation and High Blood Pressure, sponsored by Vanderbilt University Medical Center.
NCT03753204 is a Phase 1 study of Inflammation and High Blood Pressure that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 20 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03753204, a Phase 1 study of Inflammation and High Blood Pressure, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, renal injury, and cardiovascular disease remains unclear. Our data indicated that monocytes exhibit salt sensitivity, and the investigators hypothesize that of salt sensitivity of these and similar immune cells correlate with the hypertensive response to salt intake. Currently, the research tools for diagnosing salt-sensitivity are costly, time consuming and laborious. In this study the investigators will identify monocyte salt-sensitivity as a marker of salt-sensitive hypertension.
Primary Outcome
A reduction in systolic blood pressure \>9 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive
Conditions Studied
Interventions
- DRUG Furosemide 40 mg
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
What the registry record for NCT03753204 still lists
NCT03753204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Furosemide 40 mg is the first listed.
NCT03753204 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03753204 about?
NCT03753204 is a clinical study titled "Salt-Sensitivity and Immunity Cell Activation". Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, r...
What is the current status of trial NCT03753204?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-09-01. Estimated completion is 2026-09-15.
What conditions does trial NCT03753204 study?
This clinical trial studies the following conditions: Inflammation, High Blood Pressure, Salt; Excess.
What interventions are being tested in trial NCT03753204?
The interventions under investigation include: Furosemide 40 mg (DRUG).
Who is sponsoring clinical trial NCT03753204?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03753204 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03753204's enrollment target sits among peer trials
20 119th of 132 higher than 11 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
RECRUITING · Phase 1
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
-
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
COMPLETED · Phase 1
-
Flaxseed Modulates Inflammation and Oxidative Stress in CF
COMPLETED · Phase 1
-
Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
COMPLETED · Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI